glecaprevir/pibrentasvir (Mavyret)
Jump to navigation
Jump to search
Indications
- treatment of chronic hepatitis C genotypes 1-6
- without cirrhosis, or with mild cirrhosis
- useful in patients with renal failure including those on renal dialysis[1]
- FDA-approved to treat all genotypes of hepatitis C in children[5]
Contraindications
- not recommended in patients with moderate cirrhosis
- contraindicated in patients with severe cirrhosis
Dosage
- 8 weeks of treatment[1]
- 12 weeks of treatment[2]
- 8 or 12 weeks of treatment[3][4]
- 8 weeks of treatment for treatment naive patients
Adverse effects
Drug interactions
- contraindicated in patients taking atazanavir, rifampin
More general terms
Components
References
- ↑ 1.0 1.1 1.2 Lowes R FDA OKs 8-Week Mavyret for Hepatitis C Medscape - Aug 03, 2017. http://www.medscape.com/viewarticle/883778
FDA News Release. August 3, 2017 FDA approves Mavyret for Hepatitis C https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ 2.0 2.1 Forns X, Lee SS, Valdes J et al Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet. Aug 14, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28818546 <Internet> http://thelancet.com/journals/laninf/article/PIIS1473-3099(17)30496-6/fulltext
Ferenci P New anti-HCV drug combinations: who will benefit? Lancet. Aug 14, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28818545 <Internet> http://thelancet.com/journals/laninf/article/PIIS1473-3099(17)30486-3/fulltext - ↑ 3.0 3.1 Kwo PY, Poordad F, Asatryan A et al Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017 Aug;67(2):263-271. Epub 2017 Apr 13. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28412293
- ↑ 4.0 4.1 Zeuzem S, Foster GR, Wang S et al Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med 2018; 378:354-369. Jan 25, 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29365309 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1702417
- ↑ 5.0 5.1 FDA News Release. April 30, 2019 FDA approves first treatment for all genotypes of hepatitis C in pediatric patients. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-all-genotypes-hepatitis-c-pediatric-patients
- ↑ 6.0 6.1 FDA News Release. Sept 26, 2019 FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks. https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-adults-and-children-all-genotypes-hepatitis-c-and-compensated-cirrhosis
- ↑ Mavyret (glecaprevir/pibrentasvir) prescribing information. AbbVie Inc. Chicago, IL. August, 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209394s003lbl.pdf